Jin-Yuan Shih

Pulmonary and Respiratory Medicine · 2007–2018

A researcher in the Science corpus: 4 papers; trusts 8 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom Jin-Yuan Shih trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. L. Sequist
  2. C. Yun
  3. M. Kris

Papers from Jin-Yuan Shih's perspective

Ordered by how strongly the researchers Jin-Yuan Shih trusts endorse each paper. Same corpus, a different order for every researcher.

  1. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. (New England Journal of Medicine)
  2. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer (Cancer Discovery)
  3. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M (Nature)
  4. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib (Proceedings of the National Academy of Sciences of the United States of America)
  5. Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity (Clinical Cancer Research)
  6. Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs (Journal of the American Medical Association (JAMA))
  7. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. (Proceedings of the National Academy of Sciences of the United States of America)
  8. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. (Journal of the National Cancer Institute)
  9. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP (Proceedings of the National Academy of Sciences of the United States of America)
  10. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. (Journal of Clinical Oncology)

Their papers